Pediatric GI Lymphoma: Diagnostic Workup and Management
For pediatric gastrointestinal lymphoma, obtain tissue diagnosis through endoscopic biopsy with comprehensive immunohistochemistry and cytogenetics, followed by systemic staging with PET/CT, bone marrow biopsy, and lumbar puncture, then initiate chemotherapy as primary treatment—surgery is reserved only for complications like intussusception or perforation, not for upfront resection. 1
Diagnostic Workup Algorithm
Initial Tissue Diagnosis
- Endoscopic biopsy is the gold standard for diagnosis—obtain generous tissue samples from all suspicious lesions 1, 2
- Perform mapping biopsies if multifocal disease suspected, as lymphomas can show both small and large cell components 3
- Do NOT delay treatment to obtain tissue; if endoscopy unsafe, proceed with open biopsy only if absolutely necessary 2
Required Pathologic Studies
The tissue must undergo comprehensive analysis 1:
- Immunohistochemistry: CD20, CD10, CD3, BCL2, BCL6, Ki-67 (>95% positive in Burkitt lymphoma)
- Cytogenetics: FISH for C-MYC rearrangement (essential for Burkitt vs DLBCL differentiation)
- EBV testing: EBV-encoded RNA by in situ hybridization if immunodeficiency suspected
- Terminal deoxynucleotidyl transferase (should be negative in mature B-cell lymphomas)
Critical pitfall: Burkitt lymphoma has simple karyotype with MYC translocation as sole abnormality, while DLBCL shows variable karyotype—this distinction drives treatment intensity 1
Systemic Staging Evaluation
Mandatory studies 1:
- FDG-PET/CT or PET/MRI (preferred but don't delay treatment if unavailable)
- High-resolution CT chest/abdomen/pelvis regardless of PET availability
- Bilateral bone marrow aspirate and biopsy (involvement found in significant percentage)
- Lumbar puncture with CSF cytology (CNS involvement in ~9% of Burkitt, ~3% of DLBCL)
- Baseline echocardiogram or MUGA scan (for anthracycline cardiotoxicity monitoring)
Laboratory assessment:
- CBC with differential, comprehensive metabolic panel
- LDH (prognostic marker and tumor lysis risk)
- Uric acid (tumor lysis assessment)
- HBV testing (reactivation risk with immunotherapy)
Site-Specific Considerations
For gastric involvement:
- Test for Helicobacter pylori in all cases—if MALT lymphoma confirmed, H. pylori eradication alone may achieve complete remission 4
- Endoscopic ultrasound provides prognostic information in gastric lymphoma 3
For ileocecal/small bowel disease (most common GI site in pediatrics):
- The ileocecal region is involved in 35.6% of cases 2
- Intussusception occurs in 66.7% and is the primary surgical indication 2
Management Strategy
Primary Treatment: Chemotherapy First
Chemotherapy is the cornerstone of treatment for all pediatric GI lymphomas except H. pylori-positive gastric MALT 1, 5. The evidence strongly favors medical management:
- Upfront surgical resection delays chemotherapy initiation (median 11.5 vs 4.5 days for biopsy) without survival benefit 5
- Surgical downstaging is achieved in only a minority of cases (15% in one series) 5
- Modern chemotherapy protocols (LMB96 and newer) have excellent efficacy, reducing the relative benefit of attempted surgical debulking 6, 5
Surgical Indications (Limited and Specific)
Surgery is indicated ONLY for 2, 5:
- Intussusception with lymphoma as lead point (96.6% require enterectomy and anastomosis) 2
- Bowel perforation or impending perforation
- Complete bowel obstruction unresponsive to medical management
- Tissue diagnosis when endoscopic biopsy inadequate or unsafe (open biopsy only)
Do NOT perform upfront resection for:
- Attempted surgical downstaging (delays chemotherapy, minimal benefit) 5
- Abdominal mass without complications (biopsy sufficient) 2
- Prophylactic resection to prevent future obstruction (chemotherapy addresses this) 6
Critical Surgical Pitfalls
- Extensive upfront surgery delays systemic therapy and rarely achieves clear margins 6
- Postoperative GI complications occur in 60% of biopsy patients vs 10% of resection patients, but this must be weighed against chemotherapy delay 5
- Second surgeries required in 30-40% of patients at median 4.6 months, often for stricture formation from chemotherapy 5
- All postoperative complications in one series occurred in tumors >5 cm 7
Staging System
Use the International Pediatric NHL Staging System (IPNHLSS) published 2015, which supersedes the Murphy/St. Jude system 1:
Stage IV disease (CNS involvement) defined by:
- Any lymphoma cells in CSF cytology
- Any CNS tumor mass on imaging
- Cranial nerve palsy unexplained by extracranial tumor
- Clinical spinal cord compression
- Parameningeal extension (cranial/spinal)
Special Populations
Double/triple-hit lymphomas (MYC + BCL2/BCL6 rearrangements):
- Rare in pediatrics, more common in adolescents/young adults
- Treat identically to standard Burkitt/DLBCL in pediatric age group 1
Burkitt-like lymphoma with 11q aberration:
- More complex karyotype than Burkitt, sometimes post-transplant
- Treat same as Burkitt lymphoma 1
Gastric MALT lymphoma:
- 85% associated with H. pylori in pediatrics 4
- First-line treatment is H. pylori eradication alone—achieves complete regression in most cases
- Long-term endoscopic surveillance required (no established guidelines) 8, 4